ZGNX, Zogenix, INC.'s lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. Expecting this stock to pop, priced just under $5.00 dollars a share with a $10.00 12-24 month price target!

ZGNX - Zogenix, Inc.  The company’s lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trialsfor the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy.  Expecting this stock to pop, This extended release hydrocodone will net the company substantial profit and revenue streams, hand over fist, for years to come since everyone and their mother is addicted to Vicodin. $10.00 12-24 Month price target!

$4.97

+0.125

(+2.58%%)

ZOGENIX, INC. (ZGNX)

 

 

 inShare3

+Follow 

Check out top analysts' recommendation for ZGNX

Get a 1-Month Free Trial

Last closing price (Feb 12 4:00 EDT):

4.85 (9.98%) ? 

Return to date (1m/3m/6m/12m):

78.31% ? 

Consensus price target (1m/3m/6m/12m):

5.75

 ? 

Buy/Sell Mix (1m/3m/6m/12m):

100%/0%

 ? 

Description:

Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company’s lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California. (collapse)

Sector:

Healthcare

Industry:

Drug Manufacturers - Major

Open and Closed  Open Only  Closed Only  ? 

Analyst?	Research Firm?	Signal?	Signal Date?	Initial Price?	Price Target?	Closing Date?	Return?
Charles Graham	Unaffiliated	Buy	Dec 06, '13	3.25	6.50	Dec 06, '14	49.23%
Christopher Holterhoff	Oppenheimer & Co.	Buy	Nov 14, '13	2.86	5.00	Nov 14, '14	69.58%
Akiva Felt	Oppenheimer & Co.	Buy	Nov 14, '13	2.86		Nov 14, '14	69.58%
Annabel Samimy	Stifel Nicolaus & Company, Inc.	Buy	Oct 29, '13	2.98	5.00	Oct 29, '14	62.75%
Christopher Holterhoff	Oppenheimer & Co.	Buy	Aug 08, '12	2.07	3.00	Aug 08, '13	44.93%